Top-Rated StocksTop-RatedNASDAQ:BMEA Biomea Fusion (BMEA) Stock Price, News & Analysis $1.58 -0.03 (-1.86%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$1.59 +0.01 (+0.63%) As of 09:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biomea Fusion Stock (NASDAQ:BMEA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biomea Fusion alerts:Sign Up Key Stats Today's Range$1.56▼$1.6550-Day Range$1.39▼$2.9052-Week Range$1.29▼$13.07Volume727,279 shsAverage Volume909,940 shsMarket Capitalization$59.36 millionP/E RatioN/ADividend YieldN/APrice Target$20.10Consensus RatingBuy Company Overview Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California. Read More Biomea Fusion Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreBMEA MarketRank™: Biomea Fusion scored higher than 63% of companies evaluated by MarketBeat, and ranked 652nd out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingBiomea Fusion has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBiomea Fusion has only been the subject of 4 research reports in the past 90 days.Read more about Biomea Fusion's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biomea Fusion are expected to grow in the coming year, from ($3.93) to ($3.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomea Fusion is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomea Fusion is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomea Fusion has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biomea Fusion's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.71% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biomea Fusion has recently decreased by 2.80%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomea Fusion does not currently pay a dividend.Dividend GrowthBiomea Fusion does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.71% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biomea Fusion has recently decreased by 2.80%, indicating that investor sentiment is improving. News and Social Media3.0 / 5News Sentiment1.40 News SentimentBiomea Fusion has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Biomea Fusion this week, compared to 3 articles on an average week.Search InterestOnly 18 people have searched for BMEA on MarketBeat in the last 30 days. This is a decrease of -49% compared to the previous 30 days.MarketBeat FollowsOnly 21 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biomea Fusion insiders have not sold or bought any company stock.Percentage Held by Insiders18.42% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biomea Fusion's insider trading history. Receive BMEA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter. Email Address BMEA Stock News HeadlinesBiomea Fusion (BMEA) Q2 Loss Drops 44%August 5 at 10:21 PM | fool.comBiomea Fusion files $300M mixed securities shelfAugust 5 at 5:52 PM | msn.com[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullish for stocks. In fact, the last three times this happened, a major market pullback followed… and gold entered a decade-long bull run. If history’s any guide, the smartest move today could be positioning in gold—specifically, a handful of high-potential developers.August 6 at 2:00 AM | Golden Portfolio (Ad)Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 5 at 4:05 PM | globenewswire.comBiomea Fusion Appoints Julianne Averill to its Board of DirectorsJuly 24, 2025 | globenewswire.comWhile institutions invested in Biomea Fusion, Inc. (NASDAQ:BMEA) benefited from last week's 15% gain, retail investors stood to gain the mostJuly 15, 2025 | finance.yahoo.comBiomea Fusion, Inc. (BMEA) - Yahoo FinanceJuly 3, 2025 | ca.finance.yahoo.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Biomea Fusion (BMEA) and Cencora (COR)July 2, 2025 | theglobeandmail.comSee More Headlines BMEA Stock Analysis - Frequently Asked Questions How have BMEA shares performed this year? Biomea Fusion's stock was trading at $3.88 at the beginning of 2025. Since then, BMEA shares have decreased by 59.3% and is now trading at $1.58. How were Biomea Fusion's earnings last quarter? Biomea Fusion, Inc. (NASDAQ:BMEA) posted its earnings results on Tuesday, August, 5th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.08. When did Biomea Fusion IPO? Biomea Fusion (BMEA) raised $120 million in an IPO on Friday, April 16th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Biomea Fusion's major shareholders? Top institutional investors of Biomea Fusion include Simplex Trading LLC. Insiders that own company stock include Bihua Chen, A2a Pharmaceuticals, Inc and Michael JM Hitchcock. View institutional ownership trends. How do I buy shares of Biomea Fusion? Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biomea Fusion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biomea Fusion investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Today8/05/2025Last Earnings8/05/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BMEA CIK1840439 Webwww.biomeafusion.com Phone650-980-9099FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Price Target for Biomea Fusion$20.10 High Price Target$54.00 Low Price Target$3.00 Potential Upside/Downside+1,172.2%Consensus RatingBuy Rating Score (0-4)3.18 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($3.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$138.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-197.71% Return on Assets-134.84% Debt Debt-to-Equity RatioN/A Current Ratio2.25 Quick Ratio2.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book1.11Miscellaneous Outstanding Shares37,570,000Free Float30,651,000Market Cap$59.36 million OptionableOptionable Beta-0.14 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:BMEA) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | SponsoredMissed out on Bitcoin gains?Even bigger crypto gains coming?A crypto storm is coming Right now, conditions are in place for a historic ...Stansberry Research | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.